LAB
Standard Biotools IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$360.82M
P/E Ratio
—
EPS
$-0.15
Beta
1.42
52W High
$1.72
52W Low
$0.87
50-Day MA
$1.11
200-Day MA
$1.28
Dividend Yield
—
Profit Margin
-87.80%
Forward P/E
—
PEG Ratio
—
About Standard Biotools Inc
Standard Biotools Inc. (LAB) is a leading biotechnology firm committed to advancing the capabilities of genomic analysis and biological research through innovative tools and technologies. The company specializes in high-performance products designed specifically for laboratories focused on genomics and proteomics, significantly improving research accuracy and efficiency. By leveraging proprietary platforms, Standard Biotools empowers scientists to accelerate their discoveries and enhance the quality of their work. With a strategic position within the dynamic biotechnology landscape, LAB is poised to meet the rising demand for sophisticated analytical solutions vital to the life sciences industry.
Fundamentals
| Revenue (TTM) | $85.33M |
| Gross Profit (TTM) | $42.54M |
| EBITDA | $-82.33M |
| Operating Margin | -92.10% |
| Return on Equity | -13.10% |
| Return on Assets | -9.88% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $1.23 |
| Price-to-Book | 0.83 |
| Price-to-Sales (TTM) | 4.23 |
| EV/Revenue | 2.31 |
| EV/EBITDA | -19.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -4.00% |
| Shares Outstanding | $390.07M |
| Float | $216.90M |
| % Insiders | 2.53% |
| % Institutions | 77.43% |
Analyst Ratings
Consensus ($1.55 target)
1
Buy2
HoldData last updated: 4/8/2026